ABBV vs CVX: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Chevron Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-09.
AbbVie Inc. · Healthcare
$261.07
+1.2% upside to fair value
Grade C
High Quality
VS
Chevron Corporation · Energy
$175.91
-3.4% upside to fair value
Grade D
QuantHub Verdict
ABBV has more upside to fair value
(+1.2%).
CVX trades at a lower forward P/E
(30.4x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
CVX |
| Current Price |
$261.07 |
$175.91 |
| Fair Value Estimate |
$264.30 |
$169.96 |
| Upside to Fair Value |
+1.2%
|
-3.4%
|
| Market Cap |
$461.3B |
$350.3B |
| Forward P/E |
128.0x
|
30.4x
|
| EV / EBITDA |
31.0x
|
9.4x
|
| Price / Sales |
7.3x
|
1.9x
|
| Price / FCF |
22.1x
|
26.2x
|
| Revenue Growth YoY |
+12.4%
|
+3.2%
|
| Gross Margin |
70.7%
|
25.4%
|
| Operating Margin |
27.6%
|
8.4%
|
| Return on Equity |
68.0%
|
6.2%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
4.52%
|
3.82%
|
| Analyst Consensus |
Strong Buy
|
Buy
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology and aesthetics. The company is transitioning from its historical Humira dominance, which has faced loss of exclusivity, toward high-growth assets like Skyrizi and Rinvoq that are driving robust revenue growth of 12.4% in the most recent quarter. Despite strong revenue growth and a dura…
Chevron Corporation operates as a leading integrated oil and gas company within the energy sector, demonstrating medium business quality with a stable competitive position but facing earnings pressure as evidenced by a 36.9% decline in earnings in the most recent quarter. The stock trades at a premium valuation with a P/E trailing and forward of 30.38, EV/EBITDA of 9.41, and a P/FCF of 26.2, refl…
Accumulation Zones
| Metric |
ABBV |
CVX |
| Zone Low |
$198.23 |
$127.47 |
| Zone High |
$224.66 |
$144.47 |
| In Buy Zone? |
No
|
No
|